Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) insider Der Ploeg Leonardus H.T. Van sold 38,000 shares of the stock in a transaction on Friday, November 2nd. The shares were sold at an average price of $30.09, for a total value of $1,143,420.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Der Ploeg Leonardus H.T. Van also recently made the following trade(s):
- On Tuesday, September 25th, Der Ploeg Leonardus H.T. Van sold 31,800 shares of Rhythm Pharmaceuticals stock. The shares were sold at an average price of $29.80, for a total value of $947,640.00.
NASDAQ:RYTM opened at $29.90 on Wednesday. The firm has a market capitalization of $1.06 billion and a P/E ratio of -10.57. Rhythm Pharmaceuticals Inc has a 12 month low of $16.80 and a 12 month high of $37.23.
Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its earnings results on Wednesday, August 8th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.04). As a group, equities analysts expect that Rhythm Pharmaceuticals Inc will post -1.94 EPS for the current fiscal year.
Several brokerages have recently issued reports on RYTM. ValuEngine upgraded Rhythm Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, October 17th. BidaskClub upgraded Rhythm Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, October 18th. Needham & Company LLC set a $42.00 price objective on Rhythm Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 9th. Stifel Nicolaus began coverage on Rhythm Pharmaceuticals in a research note on Friday, September 14th. They issued a “hold” rating and a $36.00 price objective on the stock. Finally, Zacks Investment Research cut Rhythm Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 15th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Rhythm Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $38.60.
A number of large investors have recently bought and sold shares of RYTM. Bank of America Corp DE increased its holdings in Rhythm Pharmaceuticals by 110.5% in the second quarter. Bank of America Corp DE now owns 6,251 shares of the company’s stock valued at $195,000 after buying an additional 3,282 shares during the last quarter. Cubist Systematic Strategies LLC increased its holdings in Rhythm Pharmaceuticals by 642.8% in the second quarter. Cubist Systematic Strategies LLC now owns 8,735 shares of the company’s stock valued at $273,000 after buying an additional 7,559 shares during the last quarter. Highland Capital Management LP purchased a new position in Rhythm Pharmaceuticals in the second quarter valued at $313,000. Rhumbline Advisers purchased a new position in Rhythm Pharmaceuticals in the second quarter valued at $357,000. Finally, TD Asset Management Inc. purchased a new position in Rhythm Pharmaceuticals in the second quarter valued at $364,000. 87.08% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This story was first reported by Macon Daily and is the property of of Macon Daily. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://macondaily.com/2018/11/07/der-ploeg-leonardus-h-t-van-sells-38000-shares-of-rhythm-pharmaceuticals-inc-rytm-stock.html.
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its peptide candidates include Setmelanotide, a melanocortin-4 receptor agonist, which is in Phase III clinical trial to treat POMC and leptin receptor deficiency obesity; and Phase II clinical trial for Bardet-Biedl and Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders.
See Also: Fiduciary
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.